Refine by
Profiling System Articles & Analysis: Older
27 news found
Built on a commitment to high-quality standards, evidence-based medicine, and strong ethical behavior for almost a decade, Anuncia Medical Inc. is a trusted partner for neurosurgeons. About ReFlow™ System Mini and ReFlow™ Mini Flusher Available in the U.S. only, the ReFlow™ System Mini represents a platform technology designed to improve the ...
Advancements in metabolomics may prove relevant in studying the cause of late-stage PC and identifying men at heightened risk of developing aggressive prostate tumors through metabolic phenotyping. Understanding the metabolic profile differences between benign, low-grade, and high-grade cancer will clarify the progression and lead to new diagnostic testing measures. Metabolic ...
Over 58 million vials/pre-filled syringes of Eylea have been sold since its launch worldwide, with more than 8 million patient-years of experience and a well-established ocular and systemic safety profile. Aflibercept 8 mg is investigational, and its safety and efficacy have not yet been evaluated by any regulatory authority. ...
ByBayer AG
“These results, in a large patient population spanning 50 sites, further reinforce the strong safety profile of the FlowTriever System, while achieving substantial on-table clinical improvements and immediate symptom relief,” said Dr. ...
Werner Weitschies, Head of the Center for Drug Absorption and Transport at the University of Greifswald, Germany, introduced the meeting with a presentation on the extensive Esophageal proof of principle Study conducted in healthy volunteers with the EsoCap System at the University of Greifswaldi . EsoCap’s novel targeted application platform is designed to increase ...
Food and Drug Administration (FDA) 510(k) clearance of the LOBO-7 and LOBO-9 Vascular Occluders, the latest addition to the company’s LOBO® Vascular Occlusion System. The LOBO (LOw-profile Braided Occluder) system, purpose-built for fast and complete occlusion of a diverse set of peripheral arterial targets, now includes LOBO-3, ...
“With FDA approval just over a year ago and several high-profile acquisitions of the system by leading urology groups, we feel the addition of a sales & marketing leader like Rob will accelerate access to physicians and patients who will benefit from our patient-centric platform to treat ...
Microbiome precision medicine company Bio-Me today announced that Dr. Warren Flood has become CEO following his successful period as COO. Previous CEO Dr. Morten Isaksen moves up to the Board and will also continue as Chief Innovation Officer with a focus on longer term and higher-value clinical applications for the company’s Precision Microbiome Profiling (PMP™) technology. These ...
ByBio-Me
Leveraging off the proven success of the first-generation design, BIOSPHERE® MIS II utilizes a pre-loaded bone graft cannula and a streamlined trigger-based system as a bone graft delivery solution that is optimized for the unique challenges of minimally invasive surgery. BIOSPHERE® MIS II is a low-profile graft delivery system that ...
"There is a need for long-acting, local CRS treatments that deliver a targeted and constant therapeutic dose to the site of the disease, while alleviating need for daily adherence," said Dr. Ow. "This release profile is exactly what I would want in an anti-inflammatory implant and the symptom improvement observed with LYR-210 is quite meaningful. ...
Recognized for its growth potential, Sonic Incytes Medical Corp. has been named a top technology company in the 19th Annual “Ready to Rocket” list published by Rocket Builders. Ready to Rocket is a unique business recognition list that profiles technology companies with the greatest potential for growth. Each year, based on analysis of trends, Rocket Builders identifies the top ...
Since launching in 2018, the New York City-based company has focused its efforts on multiomic profiling of the immune system and building its Annotated Multiomic Immune Cell Atlas (AMICA). Now it is looking to apply findings from this work and test hypotheses generated through its profiling efforts, said Noam Solomon, Immunai's CEO and ...
ByImmunai
The collaboration aims to create standardised, stabilised live microbiota-based formulations addressing bacterial vaginosis (BV), a common vaginal infection among women of reproductive age linked to increased risk of miscarriage, problems during pregnancy and fertility issues1,2,3 The companies aim to leverage world-leading microbiome technology expertise to bring new therapeutics to this ...
BEN-2293 is a potent and selective small-molecule Pan-Trk antagonist formulated for topical delivery, with a pharmacokinetic profile designed for low systemic exposure to deliver the optimal safety and efficacy profile in the treatment of itch and inflammation associated with Atopic Dermatitis. ...
The LOBO (LOw-profile Braided Occluder) system is uniquely designed to provide interventional physicians with a single-device, “one-and-done” solution for the occlusion of a wide range of peripheral arterial targets. The LOBO system combines neurovascular-derived HDBRAID™ technology with a patented design to create a highly ...
NEC OncoImmunity AS (NOI), a subsidiary of NEC Corporation (NEC), and Oslo University Hospital (OUH) are pleased to announce that they have recently been awarded a prestigious grant from the Research Council of Norway (RCN) to develop an artificial intelligence (AI) platform that will enable the rapid design of T-cell diagnostics for emerging or endemic infectious diseases. The project will ...
Hill added, “The ALTO endograft, with its ultra-low-profile delivery system, is ideal for treating patients with small vessels and challenging access. The new system provides a unique endovascular option, representing an important advancement for physicians and their AAA ...
To date, Okami has developed the LOBO™ Vascular Occlusion System, which is uniquely designed to provide interventional physicians with a single-device, one-and-done solution for the occlusion of a wide range of arterial targets without the need for multiple embolic devices. ...
Immunai has developed a vertically-integrated platform for multi-omic single-cell profiling that offers a broader view of the immune system in states of health, disease, and treatment to examine the body’s response to stimulus. ...
ByImmunai
The Contour Neurovascular System is a unique, fine mesh braid that is deployed across the neck of the aneurysm sac and provides a combination of flow diversion and flow disruption through a single device implant. This new, lower profile system will allow physicians to access more distally challenging vascular anatomies. ...